Gee Sally, Oliver Rob, Corfield Julie, Georghiou Luke, Yuille Martin
1 Manchester Institute of Innovation Research, Manchester Business School, The University of Manchester , Manchester, United Kingdom .
2 Research and Development Directorate, Salford Royal Hospitals NHS Trust , Salford, United Kingdom .
Biopreserv Biobank. 2015 Dec;13(6):435-51. doi: 10.1089/bio.2015.0030.
This socio-economic study is based on the widely held view that there is an inadequate supply of human biological samples that is hampering biomedical research development and innovation (RDI). The potential value of samples and the associated data are thus not being realized. We aimed to examine whether the financing of biobanks contributes to this problem and then to propose a national solution. We combined three methods: a qualitative case study; literature analysis; and informal consultations with experts. The case study enabled an examination of the complex institutional arrangements for biobanks, with a particular focus on cost models. For the purposes of comparison, a typology for biobanks was developed using the three methods. We found that it is not possible to apply a standard cost model across the diversity of biobanks, and there is a deficit in coordination and sustainability and an excess of complexity. We propose that coordination across this diversity requires dedicated resources for a national biobanking distributed research infrastructure. A coordination center would establish and improve standards and support a national portal for access. This should be financed centrally by public funds, possibly supplemented by industrial funding. We propose that: a) sample acquisition continues to be costed into projects and project proposals to ensure biobanking is driven by research needs; b) core biobanking activities and facilities be supported by central public funds distributed directly to host public institutions; and c) marginal costs for access be paid for by the user.
这项社会经济研究基于一种广泛持有的观点,即人类生物样本供应不足,这阻碍了生物医学研究的发展与创新(RDI)。因此,样本及相关数据的潜在价值尚未得到实现。我们旨在研究生物样本库的资金筹集是否导致了这一问题,进而提出一项全国性的解决方案。我们结合了三种方法:定性案例研究、文献分析以及与专家的非正式磋商。该案例研究有助于考察生物样本库复杂的制度安排,尤其关注成本模式。为便于比较,运用这三种方法构建了生物样本库的类型学。我们发现,无法在各类生物样本库中应用标准成本模式,存在协调和可持续性方面的不足以及过度的复杂性。我们建议,针对这种多样性进行协调需要为国家生物样本库分布式研究基础设施投入专门资源。一个协调中心将制定并完善标准,并支持建立一个全国性的访问门户。这应由公共资金集中资助,可能辅以产业资金。我们提议:a)样本采集继续计入项目和项目提案的成本,以确保生物样本库由研究需求驱动;b)核心生物样本库活动和设施由直接分配给主办公共机构的中央公共资金提供支持;c)访问的边际成本由用户支付。